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a  b  s  t  r  a  c  t
Invasive pneumococcal disease is a relevant public health problem in Brazil, especially
among children and the elderly. In July/2010 a 10-valent pneumococcal conjugate vaccine
was  introduced to the immunization schedule of Brazilian children under two  years of age.
Between July/2010 and December/2013 we conducted a case-series study on invasive pneu-
mococcal disease in Salvador, Brazil to describe the clinical and bacteriological proﬁle of
invasive pneumococcal disease cases during the post-implementation period. Eighty-two
cases were eligible. Mean age was 31 years (interquartile range, 3–42); 17.1% and 30.5% were
under 2 years and 5 years, respectively. Pneumococcal meningitis (n = 64, 78.1%), bacteraemic
pneumococcal pneumonia (n = 12, 14.6%) and bacteraemia (n = 6, 7.3%) were the clinical syn-
dromes identiﬁed. Thirty-three different serotypes were found. Of these, serotype 14 (n = 12,
14.6%) was the most common, followed by 23F (n = 10, 12.2%), 12F (n = 8, 9.8%), 18 C (n = 5,
6.1%) and 6B (n = 5, 6.1%). Investigations conducted in Salvador in the pre-vaccine perioddid  not identify serotype 12F as one of the most prevalent serotypes. Increase of serotype
different regions of Brazil, in the post-vaccine period. Among children12F  was observed in under two years of age, the target group for 10-valent pneumococcal conjugate vaccine, 11
(78.6%) of the 14 isolated strains of Streptococcus pneumoniae belonged to vaccine serotypes;
at  least 50% of these children were not vaccinated. The relatively recent implementation of
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10-valent pneumococcal conjugate vaccine in Brazil reinforces the need to maintain
an  active surveillance of invasive pneumococcal disease cases, considering the possible
increase of invasive pneumococcal disease cases related to non-vaccine serotypes and the
changes on the clinical presentation of the disease.
© 2015 Elsevier Editora Ltda. All rights reserved.
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treptococcus pneumoniae is a major cause of meningitis, bac-
eraemic pneumonia and sepsis,1 accounting for signiﬁcant
orbidity and mortality rates worldwide.2 Invasive pneumo-
occal disease (IPD) is a relevant public health problem in
razil, especially among children and the elderly.3 In the
ecade before the implementation of 10-valent pneumococ-
al conjugate vaccine (PCV10), S. pneumoniae was responsible
or 12% of bacterial meningitis in Brazil among children aged
nder two years and older and adults.4
Pneumococcal 7-valent conjugate vaccine (PCV7) was
icensed in the United States in 2000 and accounted for sig-
iﬁcant reduction in incidence and mortality from IPD in the
S.5 A study conducted in the US presented evidence that the
accine provides herd immunity.5 However, follow up of IPD in
he same country revealed an increased incidence of invasive
isease caused by serotypes not included in PCV7 specially
9A,6 a phenomenon named replacement. Serotype replace-
ent led to the development of vaccines with larger serotype
overage,7 which are currently available.
In Brazil, PCV7 was incorporated into the National Immu-
ization Program in 2002, available only to children under ﬁve
ears of age at high risk of pneumococcal diseases.8 In July
010 PCV10 was introduced to the immunization schedule of
razilian children under two years of age.9 In addition to the
onjugate vaccines, pneumococcal 23-valent polysaccharide
accine (PPV23) is offered for individuals over two years of age
t high risk of pneumococcal disease.8
Initial evaluation of IPD after PCV10 implementation in
razil was published in 2013. A signiﬁcant reduction in inci-
ence of IPD caused by vaccine serotypes was observed among
hildren under two years of age in the São Paulo Univer-
ity Hospital.10 In the same study, there was no signiﬁcant
hange in incidence of IPD caused by non-vaccine serotypes.
eclines in hospitalizations rates for pneumonia were found
n three major cities in Brazil in the year 2011.11 A short period
f observation after implementation of PCV10, however, was
mphasized as a limitation in both studies.
The surveillance of IPD and the recognition of serotypes
hat cause greater morbidity and mortality are essential to
ssess the effectiveness of the immunization programs.12,13
dditionally, the vaccine status and presence of comorbidi-
ies play a role on the occurrence of IPD. Documentation of
PD cases is insufﬁcient in developing countries.14 Given the
ack of data on IPD in the post-vaccine period in Brazil, there is strong need for more  studies on the clinical presentation of
he disease and proﬁle of invasive strains. In this regard, the
bjective of this study was to describe the clinical and bacteri-
logical proﬁle of IPD cases diagnosed between July 2010 andDecember 2013 in Salvador, Brazil, through case-series study
on IPD.
Material  and  methods
This was a retrospective observational study, with a prospec-
tive component. Between July 2010 and December 2013 we
conducted a case-series study on IPD in Salvador, Brazil,
involving the Hospital Couto Maia (HCM), the Paediatric Centre
Professor Hosannah de Oliveira (CPPHO) and the Cerebrospinal
Fluid Laboratory (SINPEL). HCM is the referral hospital for
infectious diseases in the state, mainly for the public health
care system; CPPHO is the pediatric unit of the Federal Uni-
versity of Bahia Hospital; SINPEL performs cerebrospinal ﬂuid
(CSF) analysis of patients seen in the supplementary health
care system in the city of Salvador. IPD cases were deﬁned
by the isolation of pneumococcus from a normally sterile site
(blood or CSF). Patients with diagnosis of IPD with positive CSF
or blood cultures for S. pneumoniae in HCM, CPPHO or SINPEL,
between July 2010 and December 2013 were included in the
study. Patients for whom it was not possible to obtain contact
information were excluded.
Samples of blood or CSF for culture were obtained from
patients with clinical suspicion of IPD, according to the routine
of the centers involved. Based on the record of positive cul-
tures for S. pneumoniae, isolates were sent to the Pathology and
Molecular Biology Laboratory of the Research Centre Gonc¸alo
Moniz CPqGM/FIOCRUZ for conﬁrmation. Identiﬁcation of
S. pneumoniae was performed using standard bacteriological
techniques, including Gram stain, colony morphology on agar
media with 5% of sheep blood, optochin susceptibility (5 g
Oxoid disks) and bile solubility.
Serotyping was performed by multiplex-PCR as described
elsewhere.15,16 The isolates with negative or equivocal results
in multiplex-PCR were sent to Adolfo Lutz Institute (National
Reference Laboratory, Ministry of Health) and subjected to
Quellung reaction for deﬁnition of capsular serotype. All
isolates identiﬁed as serogroup 6 was subjected to wciN6C-
speciﬁc PCR, for the identiﬁcation of potential serotype 6C and
6D isolates.17
Clinical and demographic data (age, date of admission and
diagnosis) were collected by review of the medical charts or
from the data recorded on the request of cultures to laborato-
ries. Patients were contacted by telephone and asked to e-mail
photo of vaccination card to conﬁrm the use of pneumococcal
vaccine prior to the episode of IPD.Vaccine serotypes are those included in PCV10 (1, 4, 5, 6B,
7F, 9V, 14, 18C, 19F and 23F); vaccine related serotypes (6A,
6A/B/C, 6C, 7C, 9L/N, 9N, 18B, 19A, 23B) were deﬁned as those
not included in PCV10, but sharing the same serogroup with
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Table 1 – Demographic and clinical characteristics of 82
cases of invasive pneumococcal disease in Salvador,
Brazil, from July 2010 through December 2013.
Demographic and clinical characteristic n (%)
Age
<2 years 14 (17.1)
<5 years 25 (30.5)
≥5 years 57 (69.5)
Hospital
HCM 55 (67.1)
CPPHO 8 (9.8)
SINPEL 19 (23.1)
Sterile site of S. pneumoniae isolation
Blood 20 (24.4)
CSF 45 (54.9)
Blood and CSF 17 (20.7)
Clinical syndrome of pneumococcal disease
Meningitis 64 (78.1)
13 were isolated from patients who received PPV23. The
patients who received PPV23 were adults and had indication
for PPV23 vaccination based on their comorbidities: one was
Table 2 – Demographic and clinical characteristics of 82
cases of invasive pneumococcal disease in Salvador,
Brazil, from July 2010 through December 2013, stratiﬁed
by age at diagnosis.
Demographic and clinical
characteristic
Age
<2 years (n = 14) ≥2 years (n = 68)
n (%) n (%)
Sterile site of S. pneumoniae isolation
Blood 7 (50.0) 13 (19.1)
CSF 5 (35.7) 40 (58.8)
Blood and CSF 2 (14.3) 15 (22.1)
Clinical syndrome of pneumococcal disease
Meningitis 7 (50.0) 57 (83.8)
Pneumonia 7 (50.0) 5 (7.4)
Bacteraemia 0 (0) 6 (8.8)
Use of pneumococcal vaccine58  b r a z j i n f e c t d
the vaccine serotypes; other serotypes were considered non-
vaccine types.
Collected data were entered and analyzed in the program
SPSS version 17. For description, proportions of categorical
variables and measures of central tendency and dispersion of
continuous measurements are presented.
This project was approved by the Ethics Committee of the
Federal University of Bahia School of Medicine.
Results  and  discussion
During the period from July 2010 through December 2013, 93
cases of IPD were identiﬁed. Of these, 11 (11.8%) were excluded
because of the unavailability of clinical, epidemiological and
contact information, resulting in 82 patients, which com-
prise the study sample. Ten different serotypes (12F, 18B, 7F,
4, 23F, 6A, 22F, 6B, 34 and 28A) were isolated from individ-
uals excluded from the study. Of these 11 excluded isolates,
4 (36.4%) belonged to vaccine serotypes, 3 (27.3%) belonged
to vaccine-related serotypes and 4 (36.4%) belonged to non-
vaccine serotypes. Capsular serotypes, age information and
information on clinical syndrome of pneumococcal disease
were obtained for all 82 cases of IPD.
Mean age was 31 years (interquartile range, 3–42). Twenty-
ﬁve cases (30.5%) occurred in patients aged less than 5 years.
Of these, 14 (56%) children were under 2 years of age. In Brazil,
it was observed predominance of children under two years
among cases of IPD pre and post-PCV10 implementation.9,18
In this context, the introduction of pneumococcal conjugate
vaccines, which confer serotype-speciﬁc immunity to children
under two years of age, is an important strategy for the pre-
vention of IPD in Brazil.
Pneumococcal meningitis (n = 64, 78.1%), bacteraemic
pneumococcal pneumonia (n = 12, 14.6%) and bacteraemia
(n = 6%, 7.3%) were the clinical syndromes identiﬁed. An
international surveillance system of IPD in Latin America
also identiﬁes predominance of meningitis in Brazil, dur-
ing the pre-vaccine period.19 Nevertheless, it is established
that among IPD, pneumonia incidence is higher than that
of meningitis.1 In Brazil, blood culture collection is recom-
mended only for severe cases of pneumonia, when patients
are hospitalized.20 In contrast, in Brazil meningitis cases
should be notiﬁed and all suspected cases of meningitis must
be submitted to blood culture collection and cerebrospinal
ﬂuid collection for culture, unless a contraindication exists.21
It is possible that the incidence of pneumococcal pneumonia
in Brazil is underestimated as a consequence of these rec-
ommendations, resulting in the preponderance of meningitis
observed in this study.
Pneumococcus strains were isolated exclusively from CSF
in 45 cases (54.9%), exclusively from blood in 20 cases (24.4%)
and from both blood and CSF in 17 cases (20.7%). Demographic
and clinical characteristics of the study sample are shown in
Table 1.
Information on use of pneumococcal vaccine was available
in 39 cases. Of the 82 patients, 9 could not be contacted due
to change of telephone number or address and 8 declined to
inform. Among the 14 children under 2 years of age, the target
group for PCV10, 3 (21.4%) had received PCV10 prior to thePneumonia 12 (14.6)
Bacteraemia 6 (7.3)
episode of IPD. Of these three children, only one had received
an appropriate number of PCV10 doses for age (a total of
4 doses) and the other two children had received a single
dose of PCV10. Three serotypes were isolated (3, 6B and 9L/N)
from children under two years of age who were vaccinated.
Serotype 3 was isolated from the child who had received an
appropriate number of PCV10 doses. Among the 68 patients
aged two years and above, 4 (5.9%) were vaccinated; of these,
two children received PCV10 and the remaining two patients
received PPV23. Serotypes 6B and 14 were isolated from the
two children aged two years and above who received PCV10;
both had received a single dose of PCV10. Serotypes 6C andNo 7 (50.0) 25 (36.8)
Yes 3 (21.4) 4 (5.9)
No data 4 (28.6) 39 (57.3)
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Table 3 – Distribution of capsular serotypes of S. pneumoniae isolated from cases of invasive pneumococcal disease from
July 2010 through December 2013 according to the inclusion in PCV10.
Age n Serotype (%)
Vaccine serotypea Vaccine-related serotypeb Non-vaccine serotypec
<2 years 14 11 (78.6) 1 (7.1) 2 (14.3)
≥2 years 68 27 (39.7) 11 (16.2) 30 (44.1)
Total 82 38 (46.4) 12 (14.6) 32 (39.0)
a Serotypes included in PCV10: 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F.
b Serotypes not included in PCV10, but in the same serogroup as vaccine serotypes.
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rc Serotypes not included in PCV10, and not in the same serogroup as
n individual with HIV infection and the other one was an
ndividual with cerebrospinal ﬂuid leaks. The patients with
omorbidities are those who received PPV23. Demographic
nd clinical characteristics of study sample, stratiﬁed by age
t diagnosis are shown in Table 2.
Thirty-three different serotypes were found. Of these,
erotype 14 (n = 12, 14.6%) was the most common, followed
y 23F (n = 10, 12.2%), 12F (n = 8, 9.8%), 18 C (n = 5, 6.1%) and 6B
n = 5, 6.1%). Serotype 14 was also predominant in two studies
onducted during the pre-vaccine period.18,22 In these studies,
he most prevalent non-vaccine serotypes were 3 and 6A, and
he conjugate pneumococcal vaccines are believed to provide
ross-protection to serotype 6A.23 Unlike the present study,
n previous investigations conducted in Salvador serotype 12F
as not observed as one of the most prevalent serotypes.18,22
urveillance of IPD cases in post-vaccine period is essen-
ial to determine the inﬂuence of serotype replacement after
neumococcal vaccination on the increase of serotype 12F,
onsidering that cyclical changes in the incidence of serotypes
ay be responsible for this increase.24 Serotype 12F was
bserved as one of the most common serotypes in the post-
accine period, in different regions of Brazil.10,25 This raises
he possibility of current emergence of this serotype.
Among children under two years of age, eight serotypes
ere isolated. Of these, serotype 14 (n = 4; 28.6%) was the most
ommon. In this age group, most (78.6%) of the 14 strains
elonged to vaccine serotypes, except serotypes 11A/D, 3 and
L/N, with one isolate each. The elevated frequency of cases
nvolving vaccine-serotypes among children under two years
f age after the universal implementation of PCV10 may be
artly explained by the low vaccine uptake in the study sam-
le, in which at least 50% of children were not vaccinated.
f the 14 cases of IPD in children younger than two years,
1 (78.6%) occurred during the ﬁrst year of implementation of
CV10. During this period, PCV10 was a newly implemented
accine and therefore unknown to the population. It was nec-
ssary that those responsible for children were instructed by
ealth professionals about the need of pneumococcal vaccina-
ion and the vaccine availability. This implementation period
ay explain the low vaccine uptake among children under
wo years of age in the study sample.
Thirty-one different serotypes were isolated from individ-
als two years of age and above. Of these, 14 (n = 8, 11.8%), 12F
n = 8, 11.8%) and 23F (n = 8, 11.8%) were the most common. In
his age group, most isolates (n = 30, 44.1%) belonged to non-
accine serotypes, a pattern similar to that reported duringine serotype
the pre-vaccine period.22 The serotype distribution according
to the inclusion in PCV10 is described in Table 3.
Considering all age groups, the most frequent serotypes
isolated from blood were 14 (n = 6, 30%), 6B (n = 4, 20%) and 19A
(n = 2, 10%). From CSF, 23F (n = 9, 20%), 12F (n = 6, 13.3%) 14 (n = 4,
8.9%) and 18 C (n = 4, 8.9%) were the most prevalent. Diversity
in distribution of pneumococcal serotypes according to the
sterile site of isolation is also described by other authors and
it is probably a consequence of individual characteristics of
each serotype.26 Foster and colleagues reported that serotype
12F signiﬁcantly increases the risk of meningitis compared to
other IPD.27 In this study, the serotype 12F was the second
most prevalent among those isolated from CSF.
This study is based on a non-probability sampling and
therefore it is possible that some results presented here are an
outcome of selection bias. A case-series, however, is an appro-
priate study design to describe the clinical and bacteriological
characteristics of IPD, the main objective of this investigation.
The relatively recent implementation of PCV10 in Brazil
reinforces the need to maintain an active surveillance of IPD
cases. Maintaining surveillance of IPD in Salvador is critical to
clarify the role of PCV10 in changes on serotypes incidence,
considering the possible increase of IPD cases related to non-
vaccine serotypes.
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